Issue 156 • July 2025

Why can’t the US figure out weight loss drug prices?

Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now?

Briefing

RFK Jr axes vaccine advisory committee members

Feature

Psychedelic drug developers redesign trials to avoid Lykos faux pas

Feature

Can pharma tariffs “Make America Manufacture Again”?

Analyst Comment

The European Market Access Lag: 2021–2024

In association with

06/23/2025 09:52:28
  • Home | Why can’t the US figure out weight loss drug prices?
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Syngene Company Insight
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Precision Health Technologies Accelerator Company Insight
  • In Depth
  • Why can’t the US figure out weight loss drug prices?
  • Psychedelic drug developers redesign trials to avoid Lykos faux pas
  • Can pharma tariffs “Make America Manufacture Again”?
  • Policy changes and digital strategies guide oncology research
  • The European Market Access Lag: 2021–2024
  • Vutrisiran marks first silencer approved for ATTR-CM
  • ASCO 2025: Key highlights
  • SCHOTT Pharma Company Insight
  • Listings
  • Events
  • Excellence Awards
  • Excellence Awards 2025: Novotech
  • Buyer's Guides
  • Next issue
06/23/2025 00:00:00